Electrospun PCL/PVP Nanofibers Meshes, A Novel Bisabolol Delivery System for Antidermatophytic Treatment

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Innovation Pub Date : 2025-01-24 DOI:10.1007/s12247-025-09928-z

Somayeh Farahmand, Saber SamadiAfshar, Nafise Alsadat Shahmoradi

{"title":"Electrospun PCL/PVP Nanofibers Meshes, A Novel Bisabolol Delivery System for Antidermatophytic Treatment","authors":"Somayeh Farahmand, Saber SamadiAfshar, Nafise Alsadat Shahmoradi","doi":"10.1007/s12247-025-09928-z","DOIUrl":null,"url":null,"abstract":"<div><p>The emergence of antifungal resistance and suboptimal drug delivery systems presents a significant challenge in treating dermatophytosis, necessitating innovative therapeutic approaches. Here, we report the development of an advanced drug delivery platform utilizing electrospun nanofibers incorporating bisabolol, demonstrating superior antifungal efficacy and controlled release properties. Through systematic optimization of polymer compositions, we engineered nanofiber networks using precise combinations of polycaprolactone (PCL), polyvinylpyrrolidone (PVP), and gelatin, incorporating bisabolol at a carefully calibrated 5% w/w drug-to-polymer ratio. Comprehensive morphological characterization via scanning electron microscopy revealed that bisabolol incorporation significantly enhanced fiber uniformity and reduced diameter distributions, with the optimized PCL100/PVP80 formulation exhibiting exceptional structural integrity. This formulation demonstrated remarkable antifungal activity, producing substantial inhibition zones against clinically relevant dermatophytes: <i>Trichophyton mentagrophytes</i> (2.05–2.6 cm, <i>p</i> < 0.001), <i>Trichophyton tonsurans</i> (2.5 cm, <i>p</i> < 0.001), and <i>Alternaria alternata</i> (1.04 cm, <i>p</i> < 0.01). High-performance liquid chromatography analysis confirmed sustained drug release kinetics over 48 h, maintaining therapeutic concentrations throughout the treatment period. Cytotoxicity evaluation through MTT assays revealed outstanding biocompatibility, with the PCL100/PVP80-bisabolol formulation maintaining 81.92 ± 4.33% fibroblast viability, significantly superior to conventional formulations (<i>p</i> < 0.001). This study presents a paradigm shift in topical antifungal therapy, offering a precisely engineered, biocompatible platform that addresses current therapeutic limitations. The developed system’s demonstrated efficacy, controlled release properties, and excellent safety profile position it as a promising candidate for clinical translation in treating chronic dermatophytosis, particularly in cases resistant to conventional treatments.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09928-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The emergence of antifungal resistance and suboptimal drug delivery systems presents a significant challenge in treating dermatophytosis, necessitating innovative therapeutic approaches. Here, we report the development of an advanced drug delivery platform utilizing electrospun nanofibers incorporating bisabolol, demonstrating superior antifungal efficacy and controlled release properties. Through systematic optimization of polymer compositions, we engineered nanofiber networks using precise combinations of polycaprolactone (PCL), polyvinylpyrrolidone (PVP), and gelatin, incorporating bisabolol at a carefully calibrated 5% w/w drug-to-polymer ratio. Comprehensive morphological characterization via scanning electron microscopy revealed that bisabolol incorporation significantly enhanced fiber uniformity and reduced diameter distributions, with the optimized PCL100/PVP80 formulation exhibiting exceptional structural integrity. This formulation demonstrated remarkable antifungal activity, producing substantial inhibition zones against clinically relevant dermatophytes: Trichophyton mentagrophytes (2.05–2.6 cm, p < 0.001), Trichophyton tonsurans (2.5 cm, p < 0.001), and Alternaria alternata (1.04 cm, p < 0.01). High-performance liquid chromatography analysis confirmed sustained drug release kinetics over 48 h, maintaining therapeutic concentrations throughout the treatment period. Cytotoxicity evaluation through MTT assays revealed outstanding biocompatibility, with the PCL100/PVP80-bisabolol formulation maintaining 81.92 ± 4.33% fibroblast viability, significantly superior to conventional formulations (p < 0.001). This study presents a paradigm shift in topical antifungal therapy, offering a precisely engineered, biocompatible platform that addresses current therapeutic limitations. The developed system’s demonstrated efficacy, controlled release properties, and excellent safety profile position it as a promising candidate for clinical translation in treating chronic dermatophytosis, particularly in cases resistant to conventional treatments.

Graphical Abstract

查看原文本刊更多论文

静电纺PCL/PVP纳米纤维网，一种新型的抗皮肤真菌治疗的比abolol递送系统

抗真菌耐药性和次优给药系统的出现对治疗皮肤癣提出了重大挑战，需要创新的治疗方法。在这里，我们报道了一种先进的药物递送平台的开发，该平台利用含有比abolol的电纺纳米纤维，显示出优越的抗真菌功效和控释特性。通过对聚合物组成的系统优化，我们利用聚己内酯（PCL）、聚乙烯吡咯烷酮（PVP）和明胶的精确组合设计了纳米纤维网络，并以精心校准的5% w/w的药聚合物比加入了比abolol。通过扫描电镜进行的综合形态表征显示，掺入双abolol显著增强了纤维均匀性，减小了直径分布，优化后的PCL100/PVP80配方具有出色的结构完整性。该配方显示出显著的抗真菌活性，对临床相关的皮肤真菌：毛癣菌（2.05-2.6 cm, p < 0.001），毛癣菌（2.5 cm, p < 0.001）和alternnaria alternata （1.04 cm, p < 0.01）产生实质性的抑制区。高效液相色谱分析证实了药物在48小时内的持续释放动力学，在整个治疗期间保持治疗浓度。通过MTT试验进行的细胞毒性评估显示了出色的生物相容性，PCL100/ pvp80 -双abolol制剂保持了81.92±4.33%的成纤维细胞存活率，显著优于传统制剂（p < 0.001）。本研究提出了局部抗真菌治疗的范式转变，提供了一个精确设计的、生物相容性的平台，解决了当前治疗的局限性。该开发系统的有效性、控释特性和良好的安全性使其成为治疗慢性皮肤植物病的临床转化的有希望的候选者，特别是在对常规治疗产生抗性的情况下。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-

CiteScore

3.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.